Zhao W, Li K, Li L, Wang R, Lei Y, Yang H
Int J Mol Sci. 2024; 25(14).
PMID: 39062956
PMC: 11277139.
DOI: 10.3390/ijms25147715.
Khameneh S, Razi S, Lashanizadegan R, Akbari S, Sayaf M, Haghani K
Front Immunol. 2024; 15:1424909.
PMID: 39007129
PMC: 11239499.
DOI: 10.3389/fimmu.2024.1424909.
Plousiou M, De Vita A, Miserocchi G, Bandini E, Vannini I, Melloni M
Cancer Manag Res. 2022; 14:2119-2131.
PMID: 35791342
PMC: 9250773.
DOI: 10.2147/CMAR.S351979.
Xing L, Feng Z, Nie H, Liu M, Liu Y, Zhang X
Mol Biol Rep. 2022; 49(11):10653-10665.
PMID: 35725854
DOI: 10.1007/s11033-022-07604-w.
Ohtsuka M, Iwamoto K, Naito A, Imasato M, Hyuga S, Nakahara Y
Cancers (Basel). 2021; 13(13).
PMID: 34283058
PMC: 8267753.
DOI: 10.3390/cancers13133348.
The Role of Exosomes in Breast Cancer Diagnosis.
Piombino C, Mastrolia I, Omarini C, Candini O, Dominici M, Piacentini F
Biomedicines. 2021; 9(3).
PMID: 33803776
PMC: 8003248.
DOI: 10.3390/biomedicines9030312.
MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment.
Virga F, Quirico L, Cucinelli S, Mazzone M, Taverna D, Orso F
Cancers (Basel). 2021; 13(1).
PMID: 33401522
PMC: 7795884.
DOI: 10.3390/cancers13010127.
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes.
Moradi-Chaleshtori M, Bandehpour M, Soudi S, Mohammadi-Yeganeh S, Hashemi S
Cancer Immunol Immunother. 2020; 70(5):1323-1339.
PMID: 33140190
PMC: 10991174.
DOI: 10.1007/s00262-020-02762-x.
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation.
Li T, Mao C, Wang X, Shi Y, Tao Y
J Exp Clin Cancer Res. 2020; 39(1):224.
PMID: 33109235
PMC: 7592369.
DOI: 10.1186/s13046-020-01733-5.
MicroRNAs: As Critical Regulators of Tumor- Associated Macrophages.
Chatterjee B, Saha P, Bose S, Shukla D, Chatterjee N, Kumar S
Int J Mol Sci. 2020; 21(19).
PMID: 32992449
PMC: 7582892.
DOI: 10.3390/ijms21197117.
Targeting microRNA in hematologic malignancies.
Han Z, Rosen S, Querfeld C
Curr Opin Oncol. 2020; 32(5):535-544.
PMID: 32657797
PMC: 7755293.
DOI: 10.1097/CCO.0000000000000657.
microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy.
Kanchan R, Siddiqui J, Mahapatra S, Batra S, Nasser M
Mol Cancer. 2020; 19(1):29.
PMID: 32059676
PMC: 7023699.
DOI: 10.1186/s12943-020-1140-x.
Metabolism and Autoimmune Responses: The microRNA Connection.
Colamatteo A, Micillo T, Bruzzaniti S, Fusco C, Garavelli S, De Rosa V
Front Immunol. 2019; 10:1969.
PMID: 31555261
PMC: 6722206.
DOI: 10.3389/fimmu.2019.01969.
Exosomes of pasteurized milk: potential pathogens of Western diseases.
Melnik B, Schmitz G
J Transl Med. 2019; 17(1):3.
PMID: 30602375
PMC: 6317263.
DOI: 10.1186/s12967-018-1760-8.
The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update.
Whiteside T
Expert Rev Mol Diagn. 2018; 18(12):1029-1040.
PMID: 30406709
PMC: 6506389.
DOI: 10.1080/14737159.2018.1544494.
MicroRNAs in Autoimmunity and Hematological Malignancies.
Di Marco M, Ramassone A, Pagotto S, Anastasiadou E, Veronese A, Visone R
Int J Mol Sci. 2018; 19(10).
PMID: 30322050
PMC: 6213554.
DOI: 10.3390/ijms19103139.
miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.
Stigliani S, Morandi F, Persico L, Lagazio C, Erminio G, Scaruffi P
Oncotarget. 2018; 9(27):19014-19025.
PMID: 29721180
PMC: 5922374.
DOI: 10.18632/oncotarget.24874.
Let-7b inhibits cancer-promoting effects of breast cancer-associated fibroblasts through IL-8 repression.
Al-Harbi B, Hendrayani S, Silva G, Aboussekhra A
Oncotarget. 2018; 9(25):17825-17838.
PMID: 29707149
PMC: 5915157.
DOI: 10.18632/oncotarget.24895.
MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner.
Andriani F, Majorini M, Mano M, Landoni E, Miceli R, Facchinetti F
J Hematol Oncol. 2018; 11(1):45.
PMID: 29558956
PMC: 5861674.
DOI: 10.1186/s13045-018-0594-4.
Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.
Zakharia Y, Bhattacharya A, Rustum Y
Oncotarget. 2018; 9(12):10765-10783.
PMID: 29535842
PMC: 5828194.
DOI: 10.18632/oncotarget.24297.